NO20032795L - Substituerte pyrazinokinoksalinderivater som serotonin reseptor agonister og antagonister - Google Patents

Substituerte pyrazinokinoksalinderivater som serotonin reseptor agonister og antagonister

Info

Publication number
NO20032795L
NO20032795L NO20032795A NO20032795A NO20032795L NO 20032795 L NO20032795 L NO 20032795L NO 20032795 A NO20032795 A NO 20032795A NO 20032795 A NO20032795 A NO 20032795A NO 20032795 L NO20032795 L NO 20032795L
Authority
NO
Norway
Prior art keywords
antagonists
disorders
novel compounds
pyrazinokinoxaline
derivatives
Prior art date
Application number
NO20032795A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032795D0 (no
Inventor
Albert J Robichaud
Ian S Mitchell
Taekyu Lee
Wenting Chen
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of NO20032795D0 publication Critical patent/NO20032795D0/no
Publication of NO20032795L publication Critical patent/NO20032795L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20032795A 2000-12-20 2003-06-19 Substituerte pyrazinokinoksalinderivater som serotonin reseptor agonister og antagonister NO20032795L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25676500P 2000-12-20 2000-12-20
PCT/US2001/049374 WO2002059127A2 (en) 2000-12-20 2001-12-19 Pyrazinoquinoxaline derivatives as serotonin agonists and antagonists

Publications (2)

Publication Number Publication Date
NO20032795D0 NO20032795D0 (no) 2003-06-19
NO20032795L true NO20032795L (no) 2003-08-04

Family

ID=22973498

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032795A NO20032795L (no) 2000-12-20 2003-06-19 Substituerte pyrazinokinoksalinderivater som serotonin reseptor agonister og antagonister

Country Status (23)

Country Link
US (1) US6638934B2 (ja)
EP (1) EP1345942B9 (ja)
JP (2) JP4346307B2 (ja)
KR (1) KR20030069192A (ja)
CN (1) CN1505631A (ja)
AT (1) ATE318819T1 (ja)
AU (1) AU2002248216B2 (ja)
BG (1) BG107864A (ja)
BR (1) BR0116347A (ja)
CA (1) CA2431970A1 (ja)
DE (1) DE60117617T2 (ja)
EE (1) EE200300301A (ja)
ES (1) ES2260335T3 (ja)
HU (1) HUP0303513A3 (ja)
IL (1) IL156201A0 (ja)
IS (1) IS6850A (ja)
MX (1) MXPA03005437A (ja)
NO (1) NO20032795L (ja)
PL (1) PL366060A1 (ja)
RU (1) RU2003121406A (ja)
SK (1) SK7022003A3 (ja)
WO (1) WO2002059127A2 (ja)
ZA (1) ZA200304303B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL366060A1 (en) * 2000-12-20 2005-01-24 Bristol-Myers Squibb Pharma Company Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonists and antagonists
US7244843B2 (en) 2003-10-07 2007-07-17 Bristol-Myers Squibb Company Modulators of serotonin receptors
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
JP5173190B2 (ja) 2004-08-25 2013-03-27 武田薬品工業株式会社 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
EP2510949A4 (en) 2009-12-11 2013-11-13 Astellas Pharma Inc THERAPEUTICS FOR FIBROMYALGIA
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4183936A (en) 1972-06-19 1980-01-15 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4238607A (en) 1972-06-19 1980-12-09 Endo Laboratories Inc. Pyridopyrrolo benzheterocycles
US3914421A (en) 1972-06-19 1975-10-21 Endo Lab Pyridopyrrolobenzheterocycles for combatting depression
US4115577A (en) 1972-06-19 1978-09-19 Endo Laboratories, Inc. Pyridopyrrolobenzheterocycles
US4013652A (en) 1972-06-19 1977-03-22 Endo Laboratories, Inc. Pyridopyrrolobenzoxazine
US4219550A (en) 1978-11-09 1980-08-26 E. I. Du Pont De Nemours And Company Cis- and trans- octahydropyridopyrrolobenzheterocycles
HUT61548A (en) * 1990-08-27 1993-01-28 Sandoz Ag Process for producing indolonaphthyridine derivatives and pharmaceutical compositions comprising such compounds
NZ512765A (en) * 1998-12-17 2003-10-31 Wyeth Corp 2,3,4,4A-tetrahydro-1H-pyrazino(1,2-A)quinoxalin- 5(6H)one derivatives being 5HT2C agonists
PL366060A1 (en) * 2000-12-20 2005-01-24 Bristol-Myers Squibb Pharma Company Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonists and antagonists

Also Published As

Publication number Publication date
CN1505631A (zh) 2004-06-16
RU2003121406A (ru) 2004-12-27
EP1345942B9 (en) 2006-11-15
US20020177596A1 (en) 2002-11-28
JP4346307B2 (ja) 2009-10-21
US6638934B2 (en) 2003-10-28
JP2009215304A (ja) 2009-09-24
DE60117617T2 (de) 2007-01-25
PL366060A1 (en) 2005-01-24
CA2431970A1 (en) 2002-08-01
DE60117617D1 (de) 2006-04-27
ATE318819T1 (de) 2006-03-15
JP2004524298A (ja) 2004-08-12
BR0116347A (pt) 2004-07-06
KR20030069192A (ko) 2003-08-25
ES2260335T3 (es) 2006-11-01
EE200300301A (et) 2003-10-15
WO2002059127A2 (en) 2002-08-01
IL156201A0 (en) 2003-12-23
EP1345942A2 (en) 2003-09-24
JP5117440B2 (ja) 2013-01-16
WO2002059127A3 (en) 2002-10-03
MXPA03005437A (es) 2003-09-10
HUP0303513A3 (en) 2005-12-28
AU2002248216B2 (en) 2007-03-01
IS6850A (is) 2003-06-18
SK7022003A3 (en) 2004-08-03
NO20032795D0 (no) 2003-06-19
HUP0303513A2 (hu) 2004-01-28
EP1345942B1 (en) 2006-03-01
ZA200304303B (en) 2004-09-02
BG107864A (bg) 2004-03-31

Similar Documents

Publication Publication Date Title
NO20032798D0 (no) Substituerte pyrrolokinoliner og pyridokinoliner som serotonin agonister ogantagonister
HK1043112A1 (zh) 取代的稠杂环γ-咔啉
MXPA03005438A (es) Pirioindoles substituidos como agonistas y antagonistas de serotonina.
NO20052728L (no) Substituerte tricykliske gamma-karboliner som serotonin reseptor agonister og antagonister
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
NO20032795L (no) Substituerte pyrazinokinoksalinderivater som serotonin reseptor agonister og antagonister
GB0311349D0 (en) Therapeutic agents, compositions, preparations and uses

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application